[Skip to Navigation]
November 1967

Clearing of Resistant Psoriasis With Anthralin

Author Affiliations

Oklahoma City

From the Department of Dermatology, University of Oklahoma Medical Center, Oklahoma City.

Arch Dermatol. 1967;96(5):554-559. doi:10.1001/archderm.1967.01610050076013

Anthralin, a relatively old topical medication, has not received much attention in America until recently, in spite of good results from its use in psoriasis and other chronic dermatoses.

The present study involves treatment of 22 resistant psoriatics with a modification of the Ingram regimen, with most patients in the hospital under observation.

Response was characterized by early rapid flattening of plaques and a significant reduction in total time required for clearing when compared to responses of previous conventional therapy. Side effects were seldom significant. Histologic changes during treatment reflected the rapid response to therapy.

A review of the literature on the mechanism of action of anthralin reveals that it may function as a mitotic inhibitor of the epidermis.

Add or change institution